Peptipedia
BioregulatorPreclinicalAnimal Studies

Ventfort

A peptide bioregulator derived from blood vessel extracts that targets vascular tissue. Part of the Khavinson bioregulator family.

Preclinical research, approved in Russia as supplement
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

10-20 mg daily

Frequency

Once or twice daily

Duration

10-30 day cycles

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 10-20 mg daily via Oral capsules or sublingual, Once or twice daily. Dose range: 10-20 mg daily. Duration: 10-30 day cycles.

Timing & Administration

Administer via Oral capsules or sublingual. Frequency: Once or twice daily.

Mechanism of Action

Regulates gene expression in vascular endothelial and smooth muscle cells. Modulates transcription patterns related to vessel wall structure, elasticity, and function, supporting healthy blood vessel maintenance during aging.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical research, approved in Russia as supplement.

Side Effects & Safety

Important Warnings

  • Not FDA approved
Generally well-tolerated
limited safety data outside Russia

References

No references available.

Related Peptides

Browse all →
EpithalonBioregulator

A tetrapeptide studied for its effects on telomerase activation and potential anti-aging properties.

View profile
ThymalinBioregulator

A thymic peptide complex utilized in Russia for immune enhancement and longevity support, developed through Professor Khavinson's bioregulator peptide research.

View profile
LivagenBioregulator

A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure. Studies in elderly subjects (75-88 years) showed activation of ribosomal genes.

View profile